??????????????????, ???????????????????????????????Unfit individuals even have the choice of venetoclax as well as obinutuzumab (VO) as frontline therapy. This is based with a phase III demo that in comparison VO with ClbO in aged/unfit individuals.113 VO was exceptional with regard to reaction price and progression-cost-free survival, and had a eq